PDE5A and colorectal carcinoma: After adjustment for potential confounders, post-diagnostic use of PDE5 inhibitors was associated with a decreased risk of death due to CRC (adjusted hazard ratios (HR) = 0.82, 95% confidence intervals (CI) = 0.67–0.99).